EPISODE · Jul 16, 2025 · 4 MIN
GSK的Blenrep卷土重来，FDA再泼冷水？20250716
from 生物科技 · host Rei
“一款曾经获得加速批准、又被撤市的抗体偶联药，如今能否凭新数据重回市场？GSK的Blenrep在DREAMM系列试验中展现出潜力，但FDA仍对其眼毒性、剂量安全性和适用人群表示担忧。这不仅是一场药物命运的较量，更是一次监管与疗效之间的深度博弈。
Embed this episode
NOW PLAYING
GSK的Blenrep卷土重来，FDA再泼冷水？20250716
0:00
4:27
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 生物科技?
This episode is 4 minutes long.
When was this 生物科技 episode published?
This episode was published on July 16, 2025.
Can I download this 生物科技 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!